Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model

• Published in: mBio Vol. 13; no. 1; p. e0304421
• Main Authors: Chiba, Shiho, Kiso, Maki, Nakajima, Noriko, Iida, Shun, Maemura, Tadashi, Kuroda, Makoto, Sato, Yuko, Ito, Mutsumi, Okuda, Moe, Yamada, Shinya, Iwatsuki-Horimoto, Kiyoko, Watanabe, Tokiko, Imai, Masaki, Armbrust, Tammy, Baric, Ralph S., Halfmann, Peter J., Suzuki, Tadaki, Kawaoka, Yoshihiro
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.02.2022
• Subjects: Animals; Antiviral Agents - pharmacology; COVID-19; COVID-19 Drug Treatment; Cricetinae; favipiravir; GS-441524; Lung; Mesocricetus; remdesivir; Research Article; SARS-CoV-2; Syrian hamster; Virology; Syrian hamster; SARS-CoV-2; GS-441524; remdesivir; favipiravir

During a pandemic, repurposing drugs that are approved for other diseases is a quick and realistic treatment option. In this study, we found that co-administration of favipiravir and the remdesivir metabolite GS-441524 more effectively blocked SARS-CoV-2 replication in the lungs of Syrian hamsters t...